Wave Life Sciences prices $100M public offering of 20M shares at $5.00; pipeline updates also disclosed

Wave Life Sciences Ltd.

Underwritten public offering of 20M ordinary shares at $5.00/share, gross proceeds ~$100M; 30-day option for additional 3M shares.
Offering expected to close Dec 11, 2023; J.P. Morgan and Leerink Partners are joint book-runners.
Cash runway (including offering net proceeds and $20M GSK milestone) expected to fund operations into Q4 2025.
Initiated dosing in RestorAATion trial for WVE-006 (AATD); earned $20M GSK milestone; proof-of-mechanism data expected 2024.
INHBE clinical candidate for metabolic disorders including obesity expected Q4 2024 selection, CTA in 2025.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Wave Life Sciences Ltd. entered into Underwriting Agreement with J.P. Morgan Securities LLC and Leerink Partners LLC, as representatives of the several underwriters valued at $5.00 per Share (effective 2023-12-06).

Action: entry
Agreement: underwriting
Counterparty: J.P. Morgan Securities LLC and Leerink Partners LLC, as representatives of the several underwriters
Value: $5.00 per Share
Effective: 2023-12-06

Exact text from the filing

On December 6, 2023, Wave Life Sciences Ltd. (the “Company”, “we” or “us”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC and Leerink Partners LLC, as representatives of the several underwriters named therein (the “Underwriters”), relating to the issuance and sale in an underwritten offering (the “Offering”) by the Company of an aggregate of 20,000,000 of the Company’s ordinary shares, no par value (the “Firm Shares”), at a public offering price of $5.00 per Share.

View on SEC.gov

Browse all material agreements →

Wave Life Sciences Ltd. filing history →

Source: SEC EDGAR

accession 0001193125-23-290972

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.